Lei K J, Pan C J, Shelly L L, Liu J L, Chou J Y
Human Genetics Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892.
J Clin Invest. 1994 May;93(5):1994-9. doi: 10.1172/JCI117192.
Glycogen storage disease (GSD) type 1a is an autosomal recessive inborn error of metabolism caused by a deficiency in microsomal glucose-6-phosphatase (G6Pase), the key enzyme in glucose homeostasis. Southern blot hybridization analysis using a panel of human-hamster hybrids showed that human G6Pase is a single-copy gene located on chromosome 17. To correlate specific defects with clinical manifestations of this disorder, we identified mutations in the G6Pase gene of GSD type 1a patients. In the G6Pase gene of a compound heterozygous patient (LLP), two mutations in exon 2 of one allele and exon 5 of the other allele were identified. The exon 2 mutation converts an arginine at codon 83 to a cysteine (R83C). This mutation, previously identified by us in another GSD type 1a patient, was shown to have no detectable phosphohydrolase activity. The exon 5 mutation in the G6Pase gene of LLP converts a glutamine codon at 347 to a stop (Q347SP). This Q347SP mutation was also detected in all exon 5 subclones (five for each patient) of two homozygous patients, KB and CB, siblings of the same parents. The predicted Q347SP mutant G6Pase is a truncated protein of 346 amino acids, 11 amino acids shorter than the wild type G6Pase of 357 residues. Site-directed mutagenesis and transient expression assays demonstrated that G6Pase-Q347SP was devoid of G6Pase activity. G6Pase is an endoplasmic reticulum (ER) membrane-associated protein containing an ER retention signal, two lysines (KK), located at residues 354 and 355. We showed that the G6Pase-K355SP mutant containing a lysine-355 to stop codon mutation is enzymatically active. Our data demonstrate that the ER protein retention signal in human G6Pase is not essential for activity. However, residues 347-354 may be required for optimal G6Pase catalysis.
1a型糖原贮积病(GSD)是一种常染色体隐性遗传的先天性代谢缺陷病,由微粒体葡萄糖-6-磷酸酶(G6Pase)缺乏所致,G6Pase是葡萄糖稳态中的关键酶。利用一组人-仓鼠杂交细胞进行的Southern印迹杂交分析表明,人G6Pase是位于17号染色体上的单拷贝基因。为了将特定缺陷与该疾病的临床表现相关联,我们鉴定了1a型糖原贮积病患者G6Pase基因中的突变。在一名复合杂合子患者(LLP)的G6Pase基因中,在一个等位基因的第2外显子和另一个等位基因的第5外显子中鉴定出两个突变。第2外显子突变使83位密码子处的精氨酸转变为半胱氨酸(R83C)。我们之前在另一名1a型糖原贮积病患者中鉴定出了该突变,结果显示其没有可检测到的磷酸水解酶活性。LLP患者G6Pase基因的第5外显子突变将347位的谷氨酰胺密码子转变为一个终止密码子(Q347SP)。在两名纯合子患者KB和CB(同一对父母的同胞)的所有第5外显子亚克隆(每位患者5个)中也检测到了这种Q347SP突变。预测的Q347SP突变型G6Pase是一种346个氨基酸的截短蛋白,比野生型357个残基的G6Pase短11个氨基酸。定点诱变和瞬时表达分析表明,G6Pase-Q347SP缺乏G6Pase活性。G6Pase是一种与内质网(ER)膜相关的蛋白,含有一个内质网滞留信号,即位于354和355位残基处的两个赖氨酸(KK)。我们发现,含有赖氨酸355至终止密码子突变的G6Pase-K355SP突变体具有酶活性。我们的数据表明,人G6Pase中的内质网蛋白滞留信号对活性并非必需。然而,347 - 354位残基可能是G6Pase最佳催化所必需的。